MASP-3 Inhibitory Antibodies for Selective Complement Pathway Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current complement inhibitors primarily target downstream molecules, such as C5, which do not effectively inhibit the initiation of complement activation, leading to potential host tissue damage in various disease states, and there is a need for inhibitors that can specifically target the initiation steps of complement activation.
Innovation Solution
Development of a monoclonal antibody or antigen-binding fragment that specifically binds to the serine protease domain of human MASP-3 with high affinity, inhibiting the alternative pathway of complement activation without affecting the classical pathway, and reducing hemolysis and opsonization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If downstream complement molecules like C5 are targeted, then complement activation can be inhibited, but the initiation steps of complement activation remain unaffected leading to potential host tissue damage
Solution Approach 1:
The patent applies preliminary action by targeting MASP-3, an upstream initiator molecule in the lectin pathway of complement activation. By inhibiting MASP-3 before the cascade progresses to downstream effectors like C5, the invention prevents complement activation at its source, thereby avoiding host tissue damage while maintaining reliable complement inhibition. This upstream intervention strategy resolves the contradiction by acting earlier in the pathway.
2Object-affected harmful factors
If broad complement inhibition is achieved, then protective immune response is reduced, but pathogen defense capability is compromised
Solution Approach 1:
The patent applies local quality by selectively inhibiting MASP-3 in the lectin pathway while preserving other complement pathways and immune functions. This localized inhibition targets specific harmful complement activation without broadly suppressing the entire complement system, thereby maintaining host defense capability against pathogens while preventing tissue damage from uncontrolled complement activation.
3Object-affected harmful factors
If MASP-3 is specifically targeted to inhibit alternative pathway, then hemolysis and C3 cleavage are reduced, but classical pathway remains unaffected
Solution Approach 1:
The patent applies segmentation by dividing the complement system into distinct pathways and selectively inhibiting MASP-3 in the lectin/alternative pathway while leaving the classical pathway intact. This segmented approach allows specific inhibition of harmful effects like hemolysis and C3 cleavage through MASP-3 blockade, while preserving classical pathway functionality for other immune responses, thus achieving pathway-specific therapeutic action.
Data Source
AI summary
The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.